Showing posts with label Legal. Show all posts
Showing posts with label Legal. Show all posts

Friday, November 23, 2012

Singapore - Proposed law to address parentage of IVF babies


SINGAPORE - With a rising number of children born in Singapore through assisted reproductive technology (ART) such as in-vitro fertilisation (IVF), a new law is being proposed to clarify who their legal parents are.

Besides conferring legal motherhood on the woman who carries the child, the law will, more importantly, address issues of who the legal father is.

Currently, no specific legislation addresses the legal parentage of children conceived through such methods.

According to a Ministry of Health spokesman, in 2010, there were 1,308 babies conceived through ART. In 2006, only 720 were conceived through this method.

A month-long public consultation starts today on the Status of Children (Assisted Reproduction Technology) Bill, put forth by the Ministry of Law.

The Bill covers three broad scenarios: Firstly, if a child was conceived with the sperm of the mother's husband. In such cases, the husband will be treated as the legal father.

The second scenario is if the sperm used does not belong to the husband of the woman. In this instance, the husband will be treated as the legal father, if he had consented to the treatment.

Legal fatherhood is also applied if the husband accepts the child as a child of the marriage, even though he did not consent to the fertilisation procedure.

The third scenario is if the mother is unmarried, but the child is conceived with sperm from her de facto partner, or if the partner accepts the child as a child of the relationship.

In such a case, the mother, child, or partner can apply for the partner to be declared the legal father. However, the child will not be considered legitimate.

The proposed Bill will also address cases of mix-ups, when the wrong sperm or embryo is used, either through negligence or mistake.

In such scenarios, the woman and her husband who consented to the fertilisation procedure will be the legal parents.

However, for the other party whose sperm or egg was used mistakenly, he or she can apply to the court to be declared as the legal parent, voiding the legality of the previous parents. This must be done within two years of discovery of the mistake.

The public can view the consultation paper and draft Bill at www.minlaw.gov.sg and www.reach.gov.sg/YourSay/E consultationpaper.aspx.

The Bill is likely to be introduced in Parliament in the first half of next year, and may come into force by the end of next year.

Adrian Lim

Friday, August 24, 2012

USA - A Closer Look at Telemedicine's Legal Issues


Five legal issues require scrutiny prior to launching a telemedicine program.

Doctors have been practicing some form of telemedicine since before the invention of the telephone. And while the communication technology has evolved—doctors can now conduct a video consultation with colleagues in the next county or on the next continent—laws governing these events have not kept up.

There is no universal law of telemedicine, and different states take significantly different approaches to regulating it. Consequently, jumping into telemedicine without first analyzing a few critical legal issues could have serious consequences.

Following are five of the most important legal issues facing health care providers who are contemplating telemedicine.

State Licensure and Credentialing of Physicians

Health care organizations and physicians contemplating a telemedicine arrangement face complicated licensure and credentialing issues because telemedicine often involves a doctor in one state consulting with a doctor who resides in a different state or even a different country. Licensing of physicians is a state government function, and each state develops its own rules regarding physician licensure. Unfortunately for telemedicine providers, states have not adopted a uniform approach to telemedicine.

Some states, such as California and Ohio, have created specific legislative provisions addressing telemedicine, while others, such as Indiana, have not addressed it at all. Therefore, depending on the locations of the providers and the patients in a telemedicine arrangement, the providers may need a special telemedicine certificate, may need to be fully licensed in certain states or may need to do something else entirely before providing any services.

Similar issues arise with respect to physician credentialing. For example, the Joint Commission has established credentialing standards specifically addressing telemedicine. They state that the place where the patient resides retains responsibility for “overseeing the safety and quality of services offered to its patients,” but may credential telemedicine providers at distant sites under certain conditions.

Both parties must analyze licensing and credentialing issues and plan their telemedicine arrangement to ensure they are able to comply with each state’s and accrediting agency’s requirements.

Liability for Patient Injuries

If a patient is injured after receiving telemedical care, who bears the liability for the harm? The patient’s primary care physician will likely be the main target of an action that alleges malpractice or other wrongdoing if a patient is harmed. However, a consulting specialist may also be implicated. Just because the specialist engaged in a limited consultation and never physically treated the patient does not eliminate the possibility of legal liability for patient harm. Some courts have held that a physician who merely consulted with another physician about an anonymous patient’s medical care will not be held liable for injuries the patient sustains while in the primary physician’s care. However, the potential liability of the consulting physician usually increases as the physician gets more involved in the patient’s care.

Traditionally, medical malpractice liability hinges on the existence of a physician-patient relationship. Most courts examine multiple factors to determine whether a physician-patient relationship was developed and will likely continue to do so in the telemedicine context. Courts look at whether the consulting physician met the patient, reviewed the patient’s medical records, knew the patient’s name, received a fee for the consultation or exerted control over the patient’s care. To protect themselves, both the primary care physician and the consulting specialist physician should analyze, individually, their potential liability before entering into a telemedicine arrangement.

FDA and State Regulations

Depending on the types of technology used and the services provided in a telemedicine arrangement, state and federal regulations may be implicated. For example, software and hardware used to practice telemedicine may be regulated by the U.S. Food and Drug Administration as medical devices. Providers using only a telephone or simple videoconference hookup may have little to worry about as far as FDA regulations are concerned, but parties developing new telemedicine technologies may unwittingly be creating a medical device strictly regulated by the FDA.

In addition to FDA regulations, telemedicine providers must also consider state regulations. Some states have instituted specific rules governing the use of the Internet, e-mail and similar technologies when treating patients. What is commonplace and accepted in one state may be illegal in another.

Telemedicine providers should analyze the FDA implications of their telemedicine arrangement and review each relevant state’s statutes and regulations concerning the use of Internet, e-mail and related technologies in the treatment of patients.

Security of Patient Health Information

Protecting the privacy of patient health information is a critical requirement for health care providers. Although HIPAA and state privacy laws are not necessarily different in the telemedicine context, telemedicine may create additional risks of inadvertent disclosure of patient health information. The security rule sets forth numerous provisions related to the use, maintenance and disclosure of electronic patient health information. State laws provide additional restrictions on the use of patient health information. In response, providers must implement appropriate safeguards to protect patient health information exchanged in a telemedicine arrangement, including computer security measures, business associate agreements and appropriate policies controlling the use and disclosure of patient health information.

Reimbursement

Although telemedicine is gaining broader acceptance, not all telemedicine services are reimbursable. Through the Balanced Budget Act of 1997 and later the Medicare, Medicaid, and SCHIP Benefits Improvement and Protection Act of 2000, Congress took steps toward reimbursing some telemedicine services, including telemedicine consultations for Medicare beneficiaries in rural areas that have a shortage of health professionals. Whether a particular telemedicine service qualifies for reimbursement, however, depends on the exact nature of the service and strict compliance with the Medicare regulations.

As with all things Medicare, failing to comply with the regulations when seeking reimbursement for telemedicine services or seeking reimbursement for non-reimbursable services can have devastating consequences. The Department of Health & Human Services’ Office of Inspector General has been aggressively prosecuting Medicare fraud and will not hesitate to impose significant criminal and civil penalties in appropriate circumstances.

Telemedicine can play a critical role in providing access to health care, especially in underserved areas. First, however, providers must take steps to ensure they are complying with federal and state laws and regulations as well as licensing and credentialing organizations’ requirements.

David D. Storey

David D. Storey is an attorney with Baker & Daniels, Fort Wayne, Ind.

Thursday, April 12, 2012

USA - Exploring the Risk and Rewards of Stem Cell Products


The brave new world of stem cell research dangles the exciting potential for a host of leading-edge treatments that may one day help cure debilitating diseases such as Alzheimer's, Parkinson's and other maladies that today cannot be treated with modern medicine.

However, not much thought has been given to how those products might be regulated and how issues of legal liability may be addressed in a way that encourages scientific innovation but also protects the patients for whom these treatments might provide great relief.

Now, an attorney and law professor from the UCLA School of Law and a member of the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA has developed a roadmap that could help guide researchers, stem-cell product manufacturers, physicians and patients through the complex maze of imagining, creating and developing stem cell products and using them to treat disease.

"Stem cell research and its eventual applications hold enormous promise, but they also carry some significant risks," said distinguished professor of law Stephen R. Munzer, whose new article appears April 11 in the Boston University Journal of Science and Technology Law. "Our understanding of the number and gravity of those risks right now is incomplete and uncertain. Developing a plan now that details how to deal with such issues as stem-cell product liability is important because we need to think carefully and rationally about how to address these issues before the market is flooded with products."

In the article, Munzer offers suggestions on how stem cell products might be classified in the future; examines how applying existing product liability rules to stem cell products is inadequate; details the economic considerations for a stem-cell liability regime; and offers his views of what the law should be on liability for stem cells.

"One thing I detect from the stem cell scientists I've spoken to is a certain amount of judicious caution," he said. "What they don't want is to have people rushing to get something approved by the FDA and then see it result in unanticipated, unforeseeable problems."

One of the byproducts of that judicious caution, both of the risk of liability and the potential risk to patients, Munzer said, has been that scientists and biotechnology companies are initially going after the so-called low-hanging fruit of stem cell treatments -- those projects that appear to have the least amount of risk and the maximum benefit, such as treatments for retinal disease as opposed to organ regeneration.

In the article, Munzer also emphasizes the "ethics of risk," or having all those involved from the conception of an idea for a stem cell product to its eventual development, manufacture and administration, accountable for the risks they may be imposing on patients.

"The scientists who come up with the ideas for these products, the people who design them, the biotech companies that manufacture them and produce them in large numbers, and the treating physicians who ultimately will be administering these treatments all have to be accountable, as well as the FDA, which is charged with regulating them," Munzer said.

Munzer likened the anticipation for potential stem cell products to the excitement created in the 1980s and 1990s over early gene therapies and what may have been a rush to test the therapies without adequately considering the risks. That potential for new gene therapy treatments was temporarily derailed after Jesse Gelsinger, an 18-year-old, died in 1999 as a result of treatment in a gene therapy trial.

"Existing blood products, growth factors, vaccines -- we've got more understanding of how those things work, and that is not true in the case of stem cells," Munzer said. "We want to create a strict liability regime that encourages innovation but on the other hand does not encourage it so much that products are put on the market long before they should be."

Munzer suggests creating a social-insurance arrangement that would pool resources from everyone involved, from the scientists to the manufacturers to the treating physician and the patients, contributing to a fund that could eventually be used to compensate those harmed by stem cell products during their testing. His proposal is similar to the National Vaccine Injury Compensation Program, created in 1988 as a no-fault alternative to the traditional tort system created to ensure an adequate supply of vaccines, stabilize vaccine costs, and establish and maintain an accessible and efficient forum for individuals found to be injured by certain vaccines.

Munzer also recommends limiting punitive damages in stem cells cases, but only if the product has been approved by the U.S. Food and Drug Administration, the FDA regulatory requirements have been strictly followed, the risks of the products have become more understood and predictable, and the FDA has gained sufficient experience in regulating the products.

Munzer's liability roadmap could be of value to courts, lawyers and regulatory bodies in navigating what is to come in stem cell product development. It also should be considered a dynamic document, he said, that responds to what is learned in the coming decades about the creation and development of stem cell products.

"It is important to address these issues this early with as much insight as we can bring to it, recognizing that there will be, as the years go on, more information and a better understanding of what we're doing," he said. "Starting to address this now instead of waiting five to 10 years is vital, as it will be much easier to prevent potential mishaps and messes from occurring than it will be to try to clean them up later."

Munzer's article attempts to tackle problems that are on or just beyond the horizon, and looks to what has happened in the past for guidance.

"The product liability claims regarding stem cell products will require the most exacting attention to their safety and effectiveness that is possible without imposing an undue burden on manufacturers," the study states. "No existing category offers a perfect legal model for stem cell products. However, we can tease out pertinent features of these categories for tort litigation to show what might work well for stem cell products. Definitive recommendations must wait for these products to appear on the market and for their risks and rewards to become better understood over the coming decades."

ScienceDaily